Angiotech Announces Conference Call and Webcast of Second Quarter 2013 Results
Private Call and Webcast Available Only to Shareholders of Record
VANCOUVER, July 25, 2013 /CNW/ - Angiotech Pharmaceuticals, Inc. will host a conference call and webcast to review its results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013 at 1:00 PM ET (10:00 AM PT). The call and webcast will be available only to existing holders of Angiotech common stock, and only current shareholders of record will be eligible to receive financial and certain other company information. Shareholders of Angiotech will receive a notice via Computershare in advance of August 8 that will provide the details of how to attend the conference call.
As of May 2013, subsequent to the sale of Angiotech's Interventional Products Business to Argon Medical Devices, Inc. and the retirement of all outstanding long-term debt obligations, Angiotech became a fully private company, and therefore is no longer a voluntary filer of its financial information with the U.S. Securities and Exchange Commission.
Prospective purchasers of Angiotech shares in the secondary market may be eligible to receive financial or other information through the execution of a formal non-disclosure agreement. The execution of any non-disclosure agreement and the subsequent provision of financial or other company information will be at the sole discretion of Angiotech.
©2013 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech
Angiotech develops, manufactures and markets medical device products and technologies, primarily within the areas of wound closure and ophthalmology. Our strategy is to utilize our precision manufacturing capabilities and our highly targeted sales and marketing capabilities to offer novel or differentiated medical device products to patients, physicians and other medical device manufacturers or distributors.
SOURCE: Angiotech Pharmaceuticals, Inc.
Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(604) 221-7933 [email protected]
Share this article